Protillion Biosciences
Malek Faham is a seasoned expert in the fields of genetics and biotechnology, currently serving as Chief Scientist at Illumina Ventures since October 2017 and Chief Scientific Officer at AccuraGen since July 2015. Malek co-founded Sequenta Inc. and held the position of Chief Scientific Officer before its acquisition by Adaptive Biotechnologies, and also co-founded ParAllele BioScience, which was acquired by Affymetrix, where Malek served as VP of Oncology Technology Research. Other notable roles include advisory positions at Vineti and Convergent Genomics, as well as a research associate role at Stanford University's Genome Technology Center. Malek's academic foundation includes an MD and PhD in Medicine and Genetics from the University of California, San Francisco, following a BA in Biochemistry and Molecular Biology from the University of Maryland Baltimore County.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Protillion Biosciences
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.